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Summary Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3,
NO, NI, MO) have received primary systemic therapy. Response was assessed following 12 weeks of systemic
therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastec-
tomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months).
Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours
with an oestrogen receptor (ER) concentraton of > 20 fmol mb' cytosol protein. Cytotoxic therapy was
reserved for patients with tumours of ER concentration <20 fmol mg-' cytosol protein (n = 27) or when
endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate
at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy
outlined in this paper should now be tested against orthodox management by controlled randomised trial.
It has now been established from statistical analyses of large
controlled randomised trials that the long term survival of
patients with operable breast cancer can be improved by
systemic endocrine or cytotoxic therapy (Early Breast Cancer
Trialists' Collaborative Group 1988). These trials however
have not defined which therapy is most suitable for an
individual patient. Given the morbidity of cytotoxic therapy
(Glass et al., 1981) an unselective policy is not ideal. Further-
more the value of tumour oestrogen receptor status (ER) in
selecting patients for adjuvant hormonal therapy remains
controversial (Palshof et al., 1985; Rose et al., 1985; Fisher et
al., 1986; Rutquist et al., 1987; Bianco et al., 1988; Scottish
Breast Cancer Trials Committee 1987; Nolvadex Adjuvant
Trial Organisation 1988).
In 1985 we initiated a study in which local surgical treat-
ment was delayed in patients with large, but still technically
operable breast cancer until the response of the primary
tumour to systemic therapy had been assessed (Forrest et al.,
1986). We now report our experience with primary endocrine
and cytotoxic therapy in 88 such patients.
Patients and methods
Patient population
Patients were considered for entry into the study if they
presented with an invasive breast carcinoma 4 cm or greater
in diameter (T2, T3, NO, NI, MO). Patients with evidence of
tumour fixation to skin or pectoral muscle, lymphoedema of
the skin, detectable metastases on routine clinical and
radiological investigations (including bone scan) or with a
history of cardiac or mental instability were excluded from
the study. All patients were Karnofsky grade 0.
During the 4 year period between April 1985 and April
1989, 136 patients with tumours measuring 4 cm or greater
presented to the Breast Unit of Longmore Hospital, ofwhom
88 were included in this study. Sixteen patients failed to fulfil
the selection requirements, in five cases an incisional biopsy
had been performed to confirm the diagnosis and had re-
moved a large amount of tissue, while in 13 patients the
tumour was either multifocal, partly cystic, bilateral or
difficult to measure reliably. Seven patients were excluded
because they lived more than 50 miles from the hospital.
Only seven patients refused preoperative therapy, preferring
immediate mastectomy.
The mean age of the patient population studied was 53.1
years (range 33-69 years). Thirty-eight patients were
premenopausal (1 year or less since their last menstrual
period) and 50 were postmenopausal. Determination of
menopausal status in patients who had undergone hysterec-
tomy was based on serum gonadotrophin levels; patients
were defined as postmenopausal if their serum follicle-
stimulating hormone concentration was greater than 30 Ish'.
Initial assessment
An initial presentation, tumour size was assessed both
clinically and mammographically. Clinical diameters were
calculated from the mean ofeight caliper-measured diameters
taken at 22.50 axes before fine needle aspiration, tumour
volume was calculated by assuming that the tumour was
spherical (4/3nr3). Fine-needle aspiration was used to obtain
a cytological diagnosis of malignancy. Staging assessment
was then performed and involved a thorough clinical
examination supplemented by haematological (erythrocyte
sedimentation rate, full blood count), biochemical (urea and
electrolytes, liver function tests, serum calcium, phosphate
and albumin) and radiological (chest X-ray and radioisotope
bone scan) investigation. Any patient with abnormal liver
function tests had a liver ultrasound examination to exclude
the presence of overt metastasis. The philosophy of the study
was explained to all suitable patients both verbally and by
written document and informed consent obtained.
Pretreatment tumour material for histological and bio-
chemical evaluation, was obtained by incisional wedge biopsy
performed under general anaesthesia. Approximately 0.6 cm3
of tumour was removed. In order to standardise the tech-
nique this procedure was performed by one person (EDCA)
in the last 50 patients, and to aid post-therapeutic localisa-
tion of the tumour area, the tumour bed was marked by
ligaclips. In 15 patients, an involved axillary node was
excised in preference to biopsy of the primary tumour. For-
mal axillary node sampling was not initially performed but
has been routine in the last 29 patients.
The oestrogen receptor concentration of the pretreatment
biopsy was determined by the dextran-coated charcoal
adsorption method (Hawkins et al., 1975, 1981).
Systemic therapy
Of the 88 patients included within this study 41 received only
endocrine therapy, 27 received only cytotoxic therapy while
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20 received both forms of therapy. Systemic therapy was
commenced within 10 days of the wedge biopsy.
Pilot study
The first 36 patients all received primary endocrine therapy
(Anderson et al., 1989). In premenopausal women ovarian
function was ablated initially by surgical bilateral oophorec-
tomy (n = 5) and subsequently by the lutenising-hormone
releasing-hormone analogue goserelin (Zoladex ICI 118630,
subcutaneous implantation 3.6 mg depot preparation at 28
day intervals following 4 ml lignocaine local anaesthetic,
n = 7). Postmenopausal women received either tamoxifen
(20 mg per day, n = 11) or the aromatase inhibitor amino-
glutethimide (500 mg plus 40 mg hydrocortisone acetate,
n = 10). Three postmenopausal patients received goserelin as
their primary therapy. Cytotoxic therapy was reserved for
those patients whose tumours had failed to respond to
endocrine therapy. The chemotherapeutic regimen used was
four cycles of CHOP, i.e. cyclophosphamide 1 gm2,
adriamycin 50 mg m-2, vincristine 1.4 mg m2 to a maximum
of 2 g, all by i.v. bolus and oral prednisolone 40 mg per day
for 5 days. The regimen was administered every 21 days. If
cytopenia (WBC < 3,000 ml-3 or platelet count of
< 100,000 ml-3) was presented on day 21, therapy was
delayed until the cytopenia resolved. A dose adjusted course
was then given.
Selectivepolicy
Following the demonstration that no patient with an ER
concentration of <20 femtomols mg cytosol protein-'
showed significant regression while receiving endocrine
therapy (Anderson et al., 1989), and indeed two thirds pro-
gressed (Table III), a more formal selective policy was insti-
tuted on I April 1987. Endocrine therapy thereafter was
reserved only for those patients with ER-moderate/rich
tumours (> 20 fmol mg cytosol protein-', n = 25). Patients
with ER-poor tumours (ER<20 fmol mg cytosol protein-',
n = 27) or those patients with tumours un- responsive to
endocrine therapy received cytotoxic therapy (n = 7). In this
formalised protocol premenopausal patients received
goserelin (n = 9) and postmenopausal patients received the
selective peripheral aromatase inhibitor, 4-hydroxy-
androstenedione (250 mg intramuscular injection to alternate
buttocks at 14 days intervals; Ciba-Geigy CGP 32349,
n = 16). The chemotherapeutic regimen was unchanged.
Assessment ofresponse
Patients were reviewed weekly by one of us (EDCA).
Although formal assessment of tumour response was cal-
culated following completion of 12 weeks systemic therapy,
detection of any interim signs of local progression (n = 16),
such as de novo skin lymphoedema or increasing size of
tumour led to immediate cessation of endocrine therapy. If
progression was detected cytotoxic therapy was instituted
(n = 14) although two patients proceeded directly to surgery.
Statistical evaluation of response was by linear regression
analysis (Apple Mac, Statview) of the changes in tumour
volume between treatment weeks 4 to 12; earlier measure-
ments were discarded in order to allow the reaction caused
by tumour biopsy to subside (Figure 1). Response was
graded as (i) significant regression (reduction in tumour size
where the probability that the regression line deviated from
the horizontal was greater than 95% (ii) progression
(significant increase in tumour diameter where the probability
that the regression line deviated from the horizontal was
greater than 95% or signs of local advancement (iii) no
change (regression slope intermediate to response and pro-
gression).
Alterations in tumour size were also assessed radiologically
by a single mammogram, performed at 4 weekly intervals, in
the view known to give the best perspective of the tumour.
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Figure 1 Response of a postmenopausal patient with an
operable breast cancer of ER concentration 142 fmol mg cytosol
protein-' following intramuscular 4-hydroxyandrostenedione
(250mg) at 14 day intervals as shown by the arrows. Each closed
point represents tumour volume as calculated from the mean
tumour diameter, while each open point is the volume calculated
from the mean mammographic diameter. The calculated regres-
sion line had a correlation coefficient of - 0.96 and a slope of
- 9 x IO-I cm3(log) day-'. This indicates statistically significant
regression (P <0.0001, Student's t-test).
Side-effects
Side-effects of therapy were assessed at weekly clinical inter-
view. The morbidity associated with cytotoxic therapy was
reported using the WHO toxicity grading system (Miller et
al., 1981).
Definitive locoregional surgery
On completion of systemic therapy (3-6 months) mastec-
tomy with extensive skin removal and axillary node clearance
was performed in 82 patients, of whom 55 had simultaneous
reconstruction by latissimus dorsi myocutaneous flaps. In six
patients with complete clinical response, wide local excision
of the previous tumour site was preferred; this being followed
by radiotherapy in five cases. The excised specimen was
submitted to histological examination.
Patients who had shown a significant response to
preoperative endocrine therapy were continued on endocrine
therapy following definitive locoregional surgery. Premeno-
pausal patients proceded to oophorectomy, postmenopausal
patients received tamoxifen at a daily dose of 20 mg. Further
cytotoxic therapy was not given to any patient after surgery.
Survival
The follow-up period has been expressed from the time of
initiating systemic therapy to the date of analysis. The
median period of follow-up was 24 months (range 4-55
months). Locoregional relapse has been defined as recurrence
confined to the chest wall, breast or axilla. Supraclavicular
lymph node recurrence has been classified as distant meta-
stasis, in keeping with the staging classification for disease at
initial presentation (International Union Against Cancer,
1987 TMN classification).
Results
Response to endocrine therapy
Twenty-four of the 61 (39%) patients treated by initial
endocrine therapy had significant regression of their tumours
(Table III). All responding tumours had an ER concentration
of >20 fmol mg cytosol protein-'. The proportion ofpatients
achieving regression did not vary greatly in relation to theTable II Response rates in 47 patients with large operable cancers
of the breast treated with four cycles of the chemotherapeutic regime
CHOP (cyclophosphamide I gm-', adriamycin 50mgm ,
vincristine 1.4mgm-' to a maximum of 2g, all by i.v. bolus and
oral prednisolone 40 mg per day for 5 days) before definitive
locoregional surgery. The x2 test has been used to compare the
proportion responding to chemotherapy following failed endocrine
therapy in relation to ER concentration
No. with signifiicant No. with complete
regressionltotal clinical regression
Primary cytotoxic therapy
ER <20a 23/27 8
Following failed endocrine
therapy
ER <20a 8/10 4
ER >,20a 3/ljob I
Total 34/47 13
afmol mg cytosol protein-1, bstatistically significant x,2 = 5.05,
P = 0.025.
Table III Relationship between the pretreatment ER concentration
and response to 12 weeks endocrine therapy in 61 patients with large
operable cancers of the breast. The ER concentration was
determined by the dextran-coated charcoal adsorption method
Total Significant No
ER status no. regression change Progression
ER -poor 15 0 5 10
20a
ER - rich 46 24 16 6
20a
afmolmg cytosol protein-'.
type of endocrine therapy received or menopausal status and
for the purpose of this report all patients receiving endocrine
treatment have been considered together.
Of those patients responding to endocrine therapy, the
median time taken to achieve halfvolume (TI/2) was 44 days
(range 3-150 days, Figure 2). Only one tumour showed
complete clinical regression within the period of the study;
however all had residual invasive carcinoma detected by
histopathological examination. For various reasons the dura-
tion of preoperative antioestrogen therapy was prolonged
beyond 12 weeks in eight patients. Seven tumours continued
to' regress at the same rate while one tumour regarded as
static underwent a rapid reduction in size at 5 months.
Response to cytotoxic therapy
A significant reduction in tumour volume was observed in 34
of the 47 patients (72%) who received cytotoxic therapy
(Table II). Thirteen patients (27.6%) had complete clinical
regression of their tumour and eight (17%) had no histo-
logical evidence of invasive carcinoma in their mastectomy or
Table I Relationship between responses to hormonal therapy and
oestrogen receptor concentration of the primary tumour as
determined by the dextram-coated charcoal adsorption method in 61
patients with large operable breast cancer
No. ofpatients with
significant regressionltotal
ER <20a ER >20a Total
Premenopausal
Oophorectomy 0/2 2/3 2/5
Goserelin 0/3 7/13 7/16
Postmenopausal
Tamoxifen 0/5 4/6 4/11
Aminoglutethimide 0/4 4/6 4/10
4-hydroxyandrostenedione - 7/16 7/16
Goserelin 0/1 0/2 0/3
Total 0/15 24/46 24/61
afMolMg cytosol protein-'.
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wide local excision specimens; five patients had no gross
residual disease but invasive carcinoma was visible micro-
scopically. No patient showed evidence of tumour progres-
sion during treatment with chemotherapy.
The rate of regression was, on average, more rapid than
that achieved with endocrine therapy (median Tl/2 of 20
days, range 3-77 days, Figure 2). Those patients with steeper
regression slopes were more likely to achieve complete
clinical response within the time scale of the study.
There was no significant relationship between significant
regression to chemotherapy and the pretreatment variables of
age, menopausal status, initial clinical tumour size or
pathological axillary node status (Table IV). Of-those who
failed to respond to endocrine therapy, chemotherapy was
more likely to achieve regression in ER-poor tumours (Table
IV).
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Survival andpreoperative therapy
The overall, distant disease-free and disease-free survival of
all patients within the study is shown in Figure 3. Local
recurrence-free survival is shown in Figure 4. With a median
follow-up of 23 months (range 4-55 months), 18 (20%)
patients have relapsed, seven of whom have died as a result
of their disease. Of these seven patients, three had shown
failed to achieve significant regression in response to systemic
therapy. In five patients relapse was locoregional alone, six
patients had distant metastasis alone while 13 had evidence
of both. At 3 years 86% (76-96%; 95% confidence limits)
remain alive and 67% (55-79%; 95% confidence limits)
remain disease-free, with 81% (70-92%); 95% confidence
limits) having no evidence of local recurrence.
Toxicity
The side-effects experienced with endocrine treatment were
minimal. Hot flushings were noted in seven patients (37%)
receiving goserelin but were only moderately severe in two
patients. Vaginal dryness was a problem in one patient. Of
the 16 patients who received 4-hyroxyandrostenedione
Endocrine
therapy
Cytotoxic
therapy
Figure 2 Graph illustrating the difference in the time taken to
achieve half volume (T1/2) in tumours which responded to endo-
crine therapy (n = 24) and cytotoxic therapy (n = 34). The
median T1/2 of tumours responding to endocrine therapy was 44
days (range 3-150 days). The median T1/2 of tumours respond-
ing to cytotoxic therapy was 20 days (range 3-77 days).564 E.D.C. ANDERSON et al.
Table IV Relationship between pretreatment variables and significant tumour
regression following four cycles of preoperative cytotoxic therapy
(cyclophosphamide I gm-2, adriamycin 50 mg m-2, vincristine 1.4 mg m 2 to a
maximum of 2 g, all by i.v. bolus and oral prednisolone 40 mg per day for 5
days). Patients were designated postmenopausal if more than 1 year had elapsed
since their last menstrual period. Pretreatment axillary node status as determined
from histological examination fo an axillary node sample was available for 29
patients. The x2 test has been used to compare the relationship between
pretreatment variables and the proportion within each group who achieved
significant regression
No. significant
regression/total no. x2 P value
Tumour diameter
<5cm 19/26
5-<6cm 10/14 0.813 0.666
>6 cm 7/8
Age
30-39 years 3/5
40-49 years 14/18
50-59 years 13/19 0.939 0.816
>60 years 4/5
Menstrual status
Premenopausal 19/25
Postmenopausal 15/22 0.357 0.55
Oestrogen receptor concentration
<20 fmol mg cytosol protein-' 31/37
> 20 fmol mg cytosol protein-' 3/10 11.38 0.0007
Axillary lymph node status
Metastasis 15/23
No metastasis 6/6 2.88 0.09
Unavailable 5/13
Overall
survival
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adverse effects included a tender lump at the injection site
(n = 4), hot flushings (n = 2), erythematous rash on buttocks
(n = 1), and a clinically insignificant, self-limiting abnor-
mality of liver function tests (n = 2). Four patients who
received aminoglutethimide complained of nausea and
lethargy on initiation of therapy.
The chemotherapeutic regime was moderately toxic. The
principle side-effects were alopecia (100%), nausea and
vomiting (91% WHO grade 2 or greater), stomatitis (68%
WHO grade 2), dyspepsia (20%) mild dysuria (13%) and
neutropenia (26% WHO grade 2 or greater). Premature ter-
mination of therapy was required in two patients because of
nonspecific toxicity and in one on account of iliofemoral
thrombosis. There were no treatment related deaths and no
increase in morbidity associated with definitive surgery.
Axillary lymph node status
Histological assessment of axillary lymph node status was
performed in 46 patients (51%) before and in 86 patients
(98%) on completion of systemic therapy. Metastatic car-
cinoma was detected in 33 (72%) and 42 cases (49%) respec-
tively. Overall 56 patients (64%) had axillary metastases
7 detectable at some stage in their management.
Comparison of pre- and post-treatment axillary node status
was possible in 43 patients. Of the 33 patients in whom
axillary node metastasis were detected pretreatment, 14 had
no evidence of metastases following systemic therapy. Of
these eight had shown significant regression during systemic
therapy of which five were clinically complete. Axillary node
metastases were found in only one of the ten patients in
whom the pretreatment axillary node sample had failed to
demonstrate metastases. This patient did not respond to
4-hydroxyandrostenedione or proceed to chemotherapy and
48 60 so may represent a true progression of axillary node status.
'e from local re-
s of greater than Discussion
c therapy before
iod of follow-up This study was undertaken to ascertain whether appropriate
long-term systemic therapy could be selected by direct assess-
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ment of primary tumour response before surgical excision.
Experience of this novel form ofmanagement in 88 cases has
shown it to be a feasible approach.
A biopsy of the tumour was performed prior to initiation
of systemic therapy and has allowed direct correlation of
oestrogen receptor concentration to individual tumour re-
sponse. Of the first 36 patients treated by primary endocrine
therapy, no patient with a tumour of ER concentration less
than 20 fmol mg cytosol protein-' showed significant regres-
sion (Anderson et al., 1989). Thereafter a change in protocol
was instituted and primary endocrine therapy was reserved
for those patients with tumours of ER concentration
>,20 fmol mg cytosol protein 1. Individual responsiveness to
endocrine therapy, even within ER-moderate/rich tumours
however could only reliably be determined by direct observa-
tion of the effect oftherapy. In this way we have selected out
those patients in whom continuing endocrine systemic
therapy is appropriate. Such patients would appear to have
an excellent prognosis (Anderson et al., 1989). Similarly
direct objective assessment of tumour response to systemic
therapy allows cessation of endocrine therapy where it has
been demonstrated to be of no value with initiation of
chemotherapy if desired.
A variety of endocrine therapies have now been tried and
the proportion of patients achieving regression is similar to
that documented using the same agents in advanced disease
(Hawkins, 1985; Coombes, Stein & Dowsett, 1989; Nicholson
& Waler, 1989). Of particular interest is the efficacy of the
gonadotrophin-releasing hormone agonist, goserelin and the
peripheral aromatase inhibitor 4-hydroxandrostenedione in
pre- and post-menopausal women respectively. Gonado-
trophin-releasing hormone agonists produce an effect similar
to oophorectomy but without operation (Nicholson &
Walker, 1989) and would appear to be suitable for the
primary treatment of premenopausal women. Furthermore
they can be discontinued should therapy prove ineffective.
The requirement for intramuscular injection of 4-
hydroxyandrostenedione is a disadvantage and tamoxifen is
preferred for primary therapy in postmenopausal women.
Within this study cytotoxic therapy with its greater
associated toxicity was reserved for patients in whom endo-
crine therapy had failed or the likelihood of response to
endocrine therapy was minimal (i.e. patients with ER-poor or
ER-negative tumours). The proportion of such patients with
tumours which were chemosensitive was high and lies within
the observed range of 70-93% described with 'neoadjuvant' chemotherapy in more locally advanced breast cancers (Jac- quillat et al., 1988; Hortobagyi et al., 1988; Swain et al.,
1987). Of those individual tumours directly demonstrated as
endocrine-resistant however the proportion of ER-poor/ negative tumours regressing with chemotherapy paralleled that of primary chemotherapy (-80%) but the efficacy in
ER-rich tumours was much lower (30%). This difference in
response pattern may suggest a common mechanism of
failure to respond to both endocrine and cytotoxic therapies. The response to endocrine therapy was on average, slower
than that achieved with cytotoxic therapy. Within the period of the study only one patient achieved complete clinical
regression of their tumour during endocrine therapy and in
no patient was pathological remission complete. In contrast
the response to cytotoxic therapy was occasionally rapid and
in those patients with such a rapid response, complete clinical
and even complete pathological response was observed. None
of the parameters studied were able to define which patients
were more likely to achieve such complete remission.
As this study has progressed refinements have been made
to the protocol. The use of ER data to select systemic therapy has already been described. Initially axillary node
sampling was not an integral part of the pretreatment assess-
ment. Analysis of the pathological post-treatment axillary node staging of the first 43 patients demonstrated a lower
incidence (51%) of positivity than would be expected. Since
clinical axillary node staging is notoriously unreliable it was
felt that pathological staging of the axillary nodes should be
included in the preoperative assessment if survival data was
to be assessed. Of the 45 patients in whom pretreatment
axillary node status was known there was a higher incidence
of lymph node metastases (73%) which is more in keeping
with previous studies for tumours of similar stage (Carter et
al., 1989). Following therapy however only 20 (44%) had
detectable node metastases suggesting that the preliminary
figure of 51% was not due to sample bias. While it is
conceivable that axillary node sampling has simply removed
the few lymph nodes with metastatic disease it is also pos-
sible that the systemic therapy has been effective in
eradicating axillary metastases.
A possible benefit of primary systemic therapy, which we
have not yet explored, is that it may permit conservative
surgery in patients with large tumours which would otherwise
require mastectomy. The usefulness of initial systemic
therapy with the aim of avoiding mastectomy has been
reported in a series of 57 patients with large but potentially
operable breast cancers (Mansi et al., 1989). With a median
follow-up of 19 months these authors report similar response
rates, loco-regional recurrence, distant relapse and projected
overall survival rates to this study with only 18% (10/57) of
patients subsequently proceeding to mastectomy. Primary
systemic therapy however is not yet orthodox for operable
disease and we did not believe itjustified to perform less than
a mastectomy in the majority ofpatients. In future studies a
more conservative approach would be worthy of trial.
A disadvantage of preoperative systemic therapy is the
potential psychological morbidity induced by leaving the
tumour in situ while initial systemic therapy is undertaken. In
general this did not prove to be a problem even in patients
with nonresponsive disease. This was probably due to the
fact that surgical removal of the tumour, still regarded by
many patients as the critical step in their managment, was
still possible. Formal examination ofpsychological morbidity
was not however undertaken during this study, but should be
part of any future work.
In addition to the benefit ofselecting appropriate systemic
therapy, there is theoretical (Goldie & Coldman, 1979; Skip-
per 1964), experimental (Fisher et al., 1983) and clinical
(Nissen-Meyer et al., 1986; Ragaz, 1986) evidence, that early administration of systemic therapy in the treatment schedule
of patients with breast cancer may improve survival. The 3
year cumulative survival rate within this study was 86%, with
81% of patients remaining free of local recurrence. This
compares favourably to 3 year survival rates achieved with
orthodox treatment of large tumours of similar stage which
range from 65-78% (Duncan & Kerr, 1976; Sorace & Lipp-
man, 1988; Carter et al., 1989). Proof requires a controlled
randomised trial in which this selective approach is assessed
against conventional treatment, that is mastectomy followed
by combination chemotherapy in premenopausal women and
tamoxifen in postmenopausal women; such a trial is currently underway in Edinburgh.
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